Viral Infections. 1. Prophylaxis management of patient exposed to Chickenpox:
|
|
- Jacob Campbell
- 5 years ago
- Views:
Transcription
1 This document covers: 1. Chickenpox post exposure prophylaxis 2. Chickenpox treatment in immunosuppressed/on treatment patients 3. Management of immunosuppressed exposed to Measles All children with suspected malignant disease must have their immune status checked with regard to viral infections on admission as a new patient prior to any blood transfusions. The immunisation history should be documented as part of the new patient admission clerking. The agreed immune status screen for a new paediatric haematology/oncology patient is CMV IgG, HSV IgG, VZV IgG, Measles IgG and long term storage. Results from these tests must be recorded in the summary sheet at the front of the haematology/oncology notes and in the discharge summary written after the first admission. Chickenpox Incubation period: days Contagious: 2 days prior to the onset of the rash until spots are dry, may be prolonged in immunosuppressed children Peak incidence: March May and Autumn Chickenpox is highly infectious and is transmitted by personal contact or droplet spread. Incidence is seasonal with peaks in. Vesicles appear on the face and scalp, spreading to trunk and abdomen and eventually to the limbs. Susceptible individuals can develop varicella on direct contact with open shingles: either if exposed to ophthalmic shingles, or if in contact with an immunosuppressed person with shingles in whom viral shedding is greater than in an immunocompetent individual. Risk of infection from contact with an immunocompetent person with non-exposed shingles is low. 1. Prophylaxis management of patient exposed to Chickenpox: At risk immunosuppressed patients: Varicella zoster virus (VZV) antibody negative at diagnosis being treated for malignant disease for at least 6 months after completing such treatment. Post bone marrow transplant (BMT) patients (regardless of VZV status prior to BMT) until at least 12 months after finishing all immunosuppressive treatment, or longer if the individual has developed graft versus host disease. VZV negative and high dose steroids: until at least 3 months after the treatment stopped. VZV negative and immunosuppressive drugs (e.g. methotrexate) until 6 months after treatment stopped. Page 1 of 7
2 Algorithm for post exposure prophylaxis management of at risk patient: VZV status of patient If antibody status not known: Can test be done and results given within seven days of exposure? If yes, wait for results and treat appropriately If not, give VZIG without testing Antibody status known and negative: Give VZIG providing it can still be given within ten days of exposure (ideally within seven days but may attenuate up to ten days) If antibody status known and positive: VZIG is not indicated 1. Confirm VZV status of Haem/Onc patient 2. Confirm diagnosis and extent of infection in index case: disseminated zoster immunocompetent individual with exposed lesions immunosuppressed individual with localised zoster on any part of the body 3. Assess whether exposure is significant, the following are classed as significant contact if they have occurred between 48 hours before onset of a chickenpox rash and crusting of all lesions: a. in the same room (e.g. house, classroom or 2-4 bedded hospital bay for 15 minutes or more) or b. face-to-face i.e. playing together etc (kissing contact) 4. Decide whether patient requires treatment 5. If the patient meets the requirements for VZIG, this will be prescribed by the microbiology team. In all such cases contact the virology Consultant or the microbiology SpR to discuss the case and arrange urgent VZV antibody testing. 6. Inform Paediatric infectious diseases team. Page 2 of 7
3 Varicella Zoster Immune Globulin (VZIG) VZIG Doses (as per CBNF) via deep intramuscular injection using a 21G needle as the preparation is viscous. Because of the relatively large volume, consider giving half the volume in each leg. In patients with clotting disorders VZIG can be given subcutaneous. Neonate - 6 years 250mg 6-11 years 500mg years 750mg years 1000mg About half of susceptible immunosuppressed home contacts will develop clinical chickenpox despite VZIG prophylaxis, and a further 15% will be infected sub-clinically (Evans et al., 1980). Severe or fatal varicella can occur despite VZIG prophylaxis. Immunocompromised contacts given VZIG should therefore be monitored and aciclovir should be used at the first signs of illness. If a second contact occurs after 3 weeks, VZV antibody testing should be repeated. A second dose of Varicella Zoster Immune Globulin (VZIG) is required if the patient remains seronegative. NB: the administration of VZIG does not lead to serum antibody levels detectable by routine laboratory tests. Alternatives to VZIG: Aciclovir is another alternative to VZIG and is given orally at a prophylactic dose of 10mg/kg 6 hourly for 7 days starting 1 week after exposure. Valaciclovir 20mg/kg bd orally discuss with Dr Pollard or Dr Jeffrey. Intravenous immunoglobulin infusion dose: 0.4g/kg. Follow drug monograph for administration details. This should be used in patients with bleeding disorders/on anticoagulant therapy where deep IM injections may be problematic. Whichever method of prophylaxis is used the patient and family should be instructed to contact the specialist unit immediately if any suspicious skin lesions develop so that early treatment with intravenous aciclovir may be considered. Page 3 of 7
4 2. Management of patient with suspected Chickenpox First line treatment for chickenpox is inpatient intravenous aciclovir IV aciclovir dose (confirm doses in latest edition of CBNF): Neonate - 3 months 10mg/kg 8 hourly for at least 7 days. 3 months - 12 years 500mg/m 2 8 hourly usually for 5 days. Over 12 years 10mg/kg 8 hourly usually for 5 days. Discuss all patients with suspected chickenpox infection with a senior staff member. If the diagnosis is in doubt, admit and initiate treatment (which can be terminated if chickenpox subsequently becomes unlikely). Confirm suspected chickenpox infection in an immunosuppressed child take a swab from the base of a vesicular lesion (i.e. to include both vesicular fluid and cells from the base of the vesicle), place in virus transport medium, and send to the laboratory for VZV PCR. Caution: aciclovir is nephrotoxic: In obese patients, calculate on the basis of ideal weight for height. Maintain adequate hydration Monitor daily U&E, creatinine (may see a decline in renal function necessitating a dose adjustment). Give IV fluids for at least the first 24 hours. Usually treat for 10 days (usually at least 7 days being IV treatment) Dosing changes (as per CBNF): o Creatinine clearance ml/min/1.73m 2 give dose 12 hourly o Creatinine clearance ml/min/1.73m 2 give dose 24 hourly. In well patients, treatment may be completed at home on oral treatment only after discussion with a senior member of staff: Oral aciclovir treatment dose (CBNF): o 1 month - 12 years 20mg/kg (max 800mg) 4 times daily. o years 800mg 5 times daily. Oral valaciclovir treatment (CBNF) o Patients within 6 months of completing chemotherapy and not considered very high risk, or who develop chickenpox post VZIG may be treated with oral valaciclovir on recommendation by Dr Jeffery or Prof Pollard only. (Dose 20mg/kg tds for 7-10 days or for children years 1g tds for 7-10 days.) Page 4 of 7
5 Shingles (Herpes Zoster) Shingles is caused by a reactivation of the patient s varicella virus. Immunocompromised patients who develop shingles can usually treated on an outpatient basis with oral aciclovir (doses as for chickenpox) and chemotherapy may be continued provided the patient is kept under regular review. Treatment should be initiated within 72 hours of the onset of the rash, and continued for 7-10 days. If the patient is particularly high risk, if lesions do not heal or the condition progresses, consider stopping chemotherapy and treating with IV aciclovir. Shingles Prophylaxis: primary/secondary Post BMT/autologous rescue patients are treated with acyclovir to prevent recurrence of VZV or HSV (herpes simplex virus). Patients who have experienced recurrent or persistent chickenpox in treatment. Varicella Vaccine Recommendations The Varicella Vaccine is not routinely recommended for use in children with malignancies, but may be used on a compassionate basis in children with leukaemia. 85% of children with ALL during maintenance therapy have serologic evidence of an immune response after receiving one dose, and more that 90% after two doses, independent of whether chemotherapy is withheld or not. Immunocompromised children have a higher incidence of vaccine associated varicella than healthy children (up to 40% versus <5%); however, the vaccine associated illness usually has an extremely mild, often sub clinical course. Also, the vaccine provides a protective effect against zoster and, with a booster, reduces the risk from 15% to 3%. If a decision is taken to administer: It should be administered to susceptible children with ALL during maintenance, 12 months after documented remission. Give 2 doses (first confers immunity, second dose given 3 months later boosts the antibody titre). Check antibody titre at least 8 weeks later. How to give the vaccine Chemotherapy should be interrupted for 1 week before and 1 week after the patient receives the vaccine i.e. in a 4 week cycle of vincristine and dexamethasone, stop oral 6-Mercaptopurine and methotrexate 1 week after vincristine and dexamethasone. (It is not necessary to interrupt therapy for the second injection). Page 5 of 7
6 A full blood count should be checked at the time of vaccination, and the absolute lymphocyte count should be at least 0.7 x 10 9 /l. OUH uses Varilrix vaccine, given subcutaneous, preferably into the deltoid region. Vaccinated children should be kept in isolation from other immunocompromised children for 4-5 weeks after the vaccine due to the possibility of vaccine associated varicella. Cases of varicella zoster are reported after immunisation these maybe treated with aciclovir given intravenously if clinically severe. Attempts should be made to culture the virus and establish whether it is vaccine or wild type. NB it is highly recommended that siblings and carers who have not had chickenpox and are VZV negative be offered vaccination via the GP. 3. Management of immunosuppressed exposed to measles Measles Incubation period: Approximately 10 days (7 18 days) Contagious: onset of prodromal symptoms until four days after the appearance of the rash. Peak incidence: Autumn Diagnostic investigation: IgM in the saliva between 3 days - 6 weeks after the onset of the rash or parotid swelling Measles can be fatal in immunocompromised children, usually as a result of encephalitis or pneumonia. The following children fall into this group: Still receiving chemotherapy Post BMT (bone marrow transplant) patients until at least 12 months after finishing all immunosuppressive treatment or longer if the individual has developed graft versus host disease. All patients receiving high dose steroids until at least 3 months after the treatment has stopped. Patients receiving other types of immunosuppressive drugs (e.g. methotrexate) until 6 months after treatment Page 6 of 7
7 Regardless of antibody status (neither previous vaccination nor a low level of antibody will guarantee protection in the profoundly immunosuppressed). 1. Confirm diagnosis in index case: Clinically diagnosed or virologically confirmed disease if possible (do not wait confirmation if delay expected). 2. Significant contact would be: a. play or direct contact for 15 minutes with index case. b. contact during the infectious period i.e. between 5 day prior to until 4 day after the onset of the rash. 3. Passive immunisation with Human Immunoglobulin: As soon as possible if within 14 days of contact (ideally within 6 days but most effective if within 72 hours). Use Human Normal Immunoglobulin administered intramuscularly in the upper outer quadrant of the buttock or anterolateral thigh. If more than 3ml is to be given to a young child, or more than 5ml to older child, the immunoglobulin should be divided into smaller amounts and given in different sites. Dose: under 1 year 250mg 1 3 years 500mg over 3 years 750mg Alternatively if thrombocytopenia give intravenous immunoglobulin infusion. The dose is 0.4g/kg. Follow drug monograph for administration details. This will provide approximately four weeks protection. NB there is no specific drug treatment for measles nurse in isolation off the oncology unit. Review Name Revision Date Version Review date Dr Sheila Lane, New doc June June 2012 Paed Oncology Consultant Dr Shaun Wilson, Paed Oncology Consultant Format change Significant process update Sept 2015 Sept 2017 Page 7 of 7
LRI Children s Hospital. Management of chicken pox exposure in paediatrics
LRI Children s Hospital Management of chicken pox exposure in paediatrics Staff relevant to: Clinical staff working within the UHL Children s Hospital. Team approval date: October 018 Version: V 3 Revision
More informationAtlantic Provinces Pediatric Hematology Oncology Network Réseau d oncologie et d hématologie pédiatrique des provinces de l Atlantique
Atlantic Provinces Pediatric Hematology Oncology Network Réseau d oncologie et d hématologie pédiatrique des provinces de l Atlantique Reviewed and approved by specialists at the IWK Health Centre, Halifax,
More informationChickenpox Procedure. (IPC Policy Manual)
Chickenpox Procedure (IPC Policy Manual) DOCUMENT CONTROL: Version: 1 Ratified by: Clinical Policy Approval Group Date ratified: 3 July 2018 Name of originator/author: Senior Clinical Nurse Specialist
More informationRecommendations for VZV management in. Dan Engelhard, Pierre Reusser, Rafael de la Camara, Hermann Einsele, Jan Styczynski, Kate Ward, Per Ljungman
Recommendations for VZV management in patients Cas cliniques with leukemia Dan Engelhard, Pierre Reusser, Rafael de la Camara, Hermann Einsele, Jan Styczynski, Kate Ward, Per Ljungman Introduction Acute
More informationTo provide guidance on prevention and control of illness caused by varicella-zoster virus (VZV).
Effective Date: 04/18 Replaces: 0 4 / 1 3 / 1 7 Page 1 of 4 POLICY: To provide guidance on prevention and control of illness caused by varicella-zoster virus (VZV). DEFINITIONS Two syndromes occur from
More informationVaccination to protect against shingles
Vaccination to protect against shingles - An update for registered healthcare practitioners The programme from September 2018 and contraindications and precautions Revised July 2018 NES and HPS accept
More informationGuidelines for immunisation of children following treatment with high dose chemotherapy and Haematopoietic Stem Cell Transplantation (HSCT)
Guidelines for immunisation of children following treatment with high dose chemotherapy and Haematopoietic Stem Cell Transplantation (HSCT) Version 2.0 Approved by Haem / Onc Senior Clinical Management
More informationA summary of guidance related to viral rash in pregnancy
A summary of guidance related to viral rash in pregnancy Wednesday 12 th July 2017 Dr Rukhsana Hussain Introduction Viral exanthema can cause rash in pregnant women and should be considered even in countries
More informationSouthern Derbyshire Shared Care Pathology Guidelines. Varicella Zoster Virus (VZV)
Southern Derbyshire Shared Care Pathology Guidelines Varicella Zoster Virus (VZV) Purpose of guideline This guideline provides information about the definition of significant exposure to VZV and management
More informationGuidelines for the immunisation of children following treatment with Standard-Dose Chemotherapy
Guidelines for the immunisation of children following treatment with Standard-Dose Chemotherapy Version 2.0 Approved by Haem / Onc Senior Clinical Management team Date Approved March 2015 Ratified by:
More informationProf Dr Najlaa Fawzi
1 Prof Dr Najlaa Fawzi is an acute highly infectious disease, characterized by vesicular rash, mild fever and mild constitutional symptoms. is a local manifestation of reactivation of latent varicella
More informationSTANDARD OPERATING PROCEDURE (SOP) CHICKENPOX [VARICELLA ZOSTER VIRUS (VZV)]
Page 1 of 9 SOP Objective To ensure that patients with chickenpox (Varicella Zoster Virus) are cared for appropriately and actions are taken to minimise the risk of cross-infection. This SOP applies to
More informationSection 10.5 Varicella
Section 10.5 Varicella Chickenpox Introduction Transmission Signs and Symptoms Complications Diagnosis Treatment Infection Prevention and Control Precautions for Residents with Chickenpox Additional considerations
More informationWessex Paediatric Oncology Guidelines: Management of viral infections, viral prophylaxis and vaccination guidance
Wessex Paediatric Oncology Guidelines: Management of viral infections, viral prophylaxis and vaccination guidance Scope This guideline applies to all Paediatric Oncology patients in the region. It does
More informationVaccination to protect against shingles - An update for registered healthcare practitioners
Vaccination to protect against shingles - An update for registered healthcare practitioners The programme from September 2016 and contraindications and precautions September 2016 NES and HPS accept no
More informationShingles Procedure. (IPC Policy Manual)
Shingles Procedure (IPC Policy Manual) DOCUMENT CONTROL: Version: 1.1 Ratified by: Clinical Policy Approval Group Date ratified: 3 July 2018 Name of originator/author: Senior Clinical Nurse Specialist
More informationSpots and Pox: Contact Tracing and Follow Up for Measles and Chickenpox
Chickenpox Spots and Pox: Contact Tracing and Follow Up for Measles and Chickenpox Noelle Bessette, MPH Surveillance Specialist New Jersey Department of Health Vaccine Preventable Disease Program Caused
More informationSpots and Pox: Contact Tracing and Follow Up for Measles and Chickenpox
Spots and Pox: Contact Tracing and Follow Up for Measles and Chickenpox Noelle Bessette, MPH Surveillance Specialist New Jersey Department of Health Vaccine Preventable Disease Program Chickenpox Caused
More informationVARICELLA. Dr Louise Cooley Royal Hobart Hospital
VARICELLA Dr Louise Cooley Royal Hobart Hospital Varicella Zoster Virus (VZV): The Basics Herpes virus Exclusively human infection Primary infection: varicella (chickenpox) Neurotropic, establishing latency
More informationVARICELLA ZOSTER (CHICKENPOX/SHINGLES) INFECTION CONTROL PROCEDURE
Reference Number: UHB 076 Version Number: 2 Date of Next Review: 23 June 2018 Previous Trust/LHB Reference Number: IPCD Policy No 8 T/45 VARICELLA ZOSTER (CHICKENPOX/SHINGLES) INFECTION CONTROL PROCEDURE
More informationPatient Group Direction for Varicella vaccine Version: Varicella Start Date: 1 st April 2016 Expiry Date: 31 st March 2019
Patient Group Direction for Varicella vaccine Version: Varicella 2016.1 Start Date: 1 st April 2016 Expiry Date: 31 st March 2019 THIS PATIENT GROUP DIRECTION HAS BEEN AGREED BY THE FOLLOWING ORGANISATIONS:
More informationIMMUNISATION OF CHILDREN DURING and AFTER CANCER THERAPY
NATIONAL GUIDELINES PAEDIATRIC ONCOLOGY AND HAEMATOLOGY For the Care of Childhood Cancer in Specialist Child Cancer and Shared Care Centres. IMMUNISATION OF CHILDREN DURING and AFTER CANCER THERAPY Date
More informationPatient Group Direction for Varicella vaccine Version: Varicella Start Date: 1 st May 2014 Expiry Date: 30 th April 2017
Patient Group Direction for Varicella vaccine Version: Varicella 2014.1 Start Date: 1 st May 2014 Expiry Date: 30 th April 2017 THIS PATIENT GROUP DIRECTION HAS BEEN AGREED BY THE FOLLOWING ORGANISATIONS:
More informationBackground Rationale for resource Note: Shingles is also known as herpes zoster. For the purpose of this resource the
Slide 1 Background The Joint Committee on Vaccination and Immunisation 1 reviewed all the available medical, epidemiological and economic evidence as well as vaccine safety and efficacy relevant to offering
More informationWrite an account on laboratory diagnosis and prevention of chickenpox virus?
Write an account on laboratory diagnosis and prevention of chickenpox virus? The clinical presentations of varicella or zoster are so characteristic that laboratory confirmation is rarely required. Laboratory
More informationIt is crucial that practitioners refer to this updated chapter when administering the shingles vaccine.
In October Public Health England published a revised Green Book chapter for shingles and also health care professional FAQs. These revisions include changes to the contraindications and precautions sections.
More informationVaccination against shingles for adults aged 70 and 79 years of age Q&A s for healthcare professionals
Vaccination against shingles for adults aged 70 and 79 years of age Q&A s for healthcare professionals Background In 2010, the Joint Committee on Vaccination and Immunisation (JCVI) 1 were asked by the
More informationEXANTHEMATOUS ILLNESS. IAP UG Teaching slides
EXANTHEMATOUS ILLNESS 1 DEFINITIONS Exanthema eruption of the skin Exanthema eruption of mucosae Macule flat nonpalpable lesion Papule small palpable lesion Nodule large palpable lesion Vesicle small fluid
More informationEssential Shared Care Agreement (South Staffordshire): Aciclovir Administration in the Community
E088 Essential Shared Care Agreement (South Staffordshire): Aciclovir Administration in the Community Patient s name: DOB NHS Number Patient s address: Consultant Note: Shared care agreement sets out a
More informationOCCUPATIONAL HEALTH DISEASE SPECIFIC RECOMMENDATIONS
Herpes simplex virus (HSV) Cold sores Genital herpes Herpetic whitlow OCCUPATIONAL HEALTH DISEASE SPECIFIC RECOMMENDATIONS contact with primary or recurrent lesions, infectious saliva or genital secretions
More informationpatient group direction
ACICLOVIR v01 1/8 ACICLOVIR PGD Details Version 1.0 Legal category Staff grades Approved by POM Paramedic (Non-ECP) Nurse (Non-ECP) Emergency Care Practitioner (Paramedic) Emergency Care Practitioner (Nurse)
More informationMANAGEMENT OF SUSPECTED VIRAL ENCEPHALITIS IN CHILDREN
MANAGEMENT OF SUSPECTED VIRAL ENCEPHALITIS IN CHILDREN OVERVIEW 1980s: dramatically improved by aciclovir HSV encephalitis in adults Delays treatment(> 48h after hospital admission): associated with a
More informationVaricella In Children With Haematological Malignancy - Outcome Of Treatment And Prevention
Varicella In Children With Haematological Malignancy - Outcome Of Treatment And Prevention C.M.L. Ho, MRCP* R. Khuzaiah, MRCP* A.M. Yasmin, MRCPath** * Department of Paediatrics, Hospital Besar, Kuala
More informationANTIBIOTIC GUIDELINES FOR THE MANAGEMENT OF COMMUNITY-ACQUIRED MENINGITIS AND ENCEPHALITIS IN ADULTS
ANTIBIOTIC GUIDELINES FOR THE MANAGEMENT OF COMMUNITY-ACQUIRED MENINGITIS AND ENCEPHALITIS IN ADULTS Version 4.0 Date ratified February 2009 Review date February 2011 Ratified by Authors Consultation Evidence
More informationNORTH AND EAST DEVON HEALTHCARE COMMUNITY SHARED CARE PRESCRIBING GUIDELINE
NORTH AND EAST DEVON HEALTHCARE COMMUNITY SHARED CARE PRESCRIBING GUIDELINE http://www.devonpct.nhs.uk/treatments/ne_devon_shared_care_guidelines.aspx#a Azathioprine Treatment of rheumatological conditions
More informationSplenectomy Vaccine Protocol PIDPIC
Splenectomy Vaccine Protocol PIDPIC 6.24.14 Rationale Spleen clears encapsulated bacteria and infected erythrocytes Serves as one of the largest lymphoid tissues where B cells are educated against encapsulated
More informationBackground Rationale for resource
Slide 1 Background The Joint Committee on Vaccination and Immunisation 1 reviewed all the available medical, epidemiological and economic evidence as well as vaccine safety and efficacy relevant to offering
More informationHealth Care Worker (Pregnant) - Infectious Diseases Risks and Exposure
1. Purpose The purpose of this guideline is to provide accurate information on the risks to pregnant Health Care Workers (HCWs) in the event of an exposure to a transmissible infectious disease at the
More informationDisseminated shingles acyclovir
Disseminated shingles acyclovir The Borg System is 100 % Disseminated shingles acyclovir Two developed disseminated herpes zoster, one developed cytomegalovirus. Reduced response to acyclovir,. Disseminated
More informationChickenpox Notification
Goolwa Campus: (08) 8555 7500 Victor Harbor Campus: (08) 8551 0900 Investigator College Chickenpox Notification Date for Distribution: 2018 Dear Parents/Caregivers There has been a case of chickenpox reported
More informationWest of Scotland Difficult Asthma Group Statement of Practice
West of Scotland Difficult Asthma Group Statement of Practice Member Health Boards: Ayrshire and Arran Dumfries and Galloway Forth Valley Lanarkshire Glasgow ADVICE NOTE FOR INTRAMUSCULAR TRIAMCINOLONE
More informationPeople with genital herpes require enough information and medication (when indicated) to self-manage their condition.
Genital Herpes Summary of Guidelines Taken from: Guidelines for the Management of Genital Herpes in New Zealand 11th Edition - 2015 www.herpes.org.nz Genital Herpes Key Management Points Genital herpes
More informationZostavax vaccine: now fully subsidised
Dermatology Infections Older person s health Virology Zostavax vaccine: now fully subsidised Zostavax is a herpes zoster (shingles) vaccine that will become fully subsidised from 1 April, 2018 for people
More informationImmunization for Adult Hematopoietic Stem Cell Transplant (HSCT) Recipients
Immunization for Adult Recipients January 4, 201 Immunization for Adult Hematopoietic Stem Cell Transplant () Recipients Revision Date: January 4, 201 Note: This guide is meant to supplement existing recommendations
More informationVARICELLA. Infectious and Tropical Pediatric Division, Department of Child Health, Medical Faculty, University of Sumatera Utara
VARICELLA (Chicken pox) Infectious and Tropical Pediatric Division, Department of Child Health, Medical Faculty, University of Sumatera Utara Definition : Varicella is a common contagious disease caused
More informationAntimicrobial Management of Febrile Neutropenic Sepsis
Antimicrobial Management of Febrile Neutropenic Sepsis Written by: Dr J Joseph, Consultant Haematologist Dr K Gajee, Consultant Microbiologist Amended by: Larissa Claybourn, Antimicrobial Pharmacist Date:
More informationA rash case Infection control management of measles
A rash case Infection control management of measles 23 th June 2013 PanCeltic Meeting Dr Jo Hargreaves Microbiology SpR University Hospital of Wales, Cardiff Acknowledgements Dr Harriet Hughes Nicola Bevan,
More informationACIVIR DT Tablets (Aciclovir)
Published on: 29 Jan 2016 ACIVIR DT Tablets (Aciclovir) Composition ACIVIR-200 DT Each dispersible tablet contains Aciclovir, BP 200 mg (in a flavoured base) ACIVIR-400 DT Each dispersible tablet contains
More informationAlphaherpesvirinae. Simplexvirus (HHV1&2/ HSV1&2) Varicellovirus (HHV3/VZV)
Alphaherpesvirinae Simplexvirus (HHV1&2/ HSV1&2) Varicellovirus (HHV3/VZV) HERPES SIMPLEX VIRUS First human herpesvirus discovered (1922) Two serotypes recognised HSV-1 & HSV-2 (1962) HSV polymorphism
More informationAzathioprine and Mercaptopurine
This guideline is currently under review. In the interim, the guideline remains valid; if GPs have any specific concerns or questions, they should seek advice from the specialist with whom they have agreed
More informationTablet Capsule shaped biconvex uncoated white to off-white tablets with 800 debossed on one side and ACV on the other side.
1. NAME OF THE MEDICINAL PRODUCT Aciclovir SUN 800 mg Tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each 800 mg tablet contains 800mg Aciclovir. For the full list of excipients, see section 6.1 3
More informationAcyclovir dose for chicken pox
Buscar... Acyclovir dose for chicken pox Acyclovir (Zovirax) treats infections caused by the herpes viruses including genital herpes, cold sores, shingles and chicken pox. Includes Acyclovir side effects.
More informationVaricella (Chickenpox) and Varicella Vaccines
Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Varicella (Chickenpox) and Varicella Vaccines September 2018 Photographs and images included in this
More informationVZV, EBV, and HHV-6-8
VZV, EBV, and HHV-6-8 Anne Gershon Common Features of Herpesviruses Morphology Basic mode of replication Primary infection followed by latency Ubiquitous Ability to cause recurrent infections (reactivation
More informationBackground Rationale for resource
Background The Joint Committee on Vaccination and Immunisation 1 reviewed all the available medical, epidemiological and economic evidence as well as vaccine safety and efficacy relevant to offering a
More informationICM VI-09 DEFINITION REFERENCES
TITLE/DESCRIPTION: MANAGEMENT OF SELECTED AIRBORNE AND DROPLET INFECTIOUS DISEASE EXPOSURES IN HEALTHCARE WORKERS INDEX NUMBER: EFFECTIVE DATE: APPLIES TO: ISSUING AUTHORITY: 01/01/2009 01/01/2013 All
More informationHIGH RISK IMMUNISATION
Overview HIGH RISK IMMUNISATION Dr. F Shaun Hosein Advanced Trainee, Public Health Medicine Sunshine Coast Public Health Unit Lecturer, University of Queensland Clinical Writer PHN Immunology Responses
More informationShingles: What s New to Know
This material was prepared by the New England Quality Innovation Network-Quality Improvement Organization (NE QIN-QIO), the Medicare Quality Improvement Organization for New England, under contract with
More informationSubunit adjuvanted zoster vaccine: why the fuss?
Subunit adjuvanted zoster vaccine: why the fuss? Soren Gantt, MD PhD MPH Pediatric Infectious Diseases Vaccine Evaluation Center BC Children s Hospital University of British Columbia Disclosures Research
More informationCiclosporin 25mg, 50mg, 100mg capsules Ciclosporin oral solution 100mg/ml
Shared Care Protocol Ciclosporin for the treatment of rheumatoid arthritis Name of drug, form and strength Background Ciclosporin 25mg, 50mg, 100mg capsules Ciclosporin oral solution 100mg/ml Ciclosporin
More informationShingles prophylaxis acyclovir
Shingles prophylaxis acyclovir Search 27-2-2018 Detailed Acyclovir dosage information for adults and TEENren. Includes dosages for Herpes Simplex - Suppression, Herpes Simplex Labialis, Herpes Zoster.
More informationPUO in the Immunocompromised Host: CMV and beyond
PUO in the Immunocompromised Host: CMV and beyond PUO in the immunocompromised host: role of viral infections Nature of host defect T cell defects Underlying disease Treatment Nature of clinical presentation
More informationDuration of treatment All DMARDs are long term treatments. Clinical benefit may take up to 6 months. 1
Leflunomide Traffic light classification- Amber 1 Information sheet for Primary Care Prescribers Part of the Shared Care Protocol: Management of Rheumatological Conditions with Disease-Modifying Anti Rheumatic
More informationPost-Transplant Vaccination and Re-Immunisation Procedure
Post-Transplant Vaccination and Re-Immunisation Procedure Table of Contents Purpose... 1 Scope/Audience... 1 Associated documents and forms... 1 Definitions... 2 Background... 2 Vaccination Recommendations...
More informationHuman Herpesviruses. VZV, EBV, and HHV-6-8. The rash of VZV is vesicular. MID 34
VZV, EBV, and HHV-6-8 Anne Gershon Human Herpesviruses Replication (lytic infection) occurs in a cascade Latency occurs when the cascade is interrupted Transcription of viral genome and protein synthesis
More informationHuman Herpesviruses. Medical Virology, 27 Nov 2015.
Human Herpesviruses Assoc.Prof. Murat Sayan Kocaeli Üniversitesi, Rutin PCR Lab. Sorumlu Öğt.Üyesi Yakın Doğu Üniversitesi, DESAM Kurucu Öğrt. Üyesi sayanmurat@hotmail.com 0533 6479020 Medical Virology,
More informationOccupational Health. Control of Measles, Mumps, Rubella and Varicella
Occupational Health Control of Measles, Mumps, Rubella and Varicella Please be advised that the Trust discourages the retention of hard copies of policies and procedures and can only guarantee that the
More informationHuman Zoster Immunoglobulin, solution for intramuscular injection.
Product Information Zoster Immunoglobulin-VF Australia NAME OF THE MEDICINE Human Zoster Immunoglobulin, solution for intramuscular injection. DESCRIPTION Zoster Immunoglobulin-VF is a sterile, preservative-free
More informationAciclovir Apotex 200 mg tabletten RVG SUMMARY OF PRODUCT CHARACTERISTICS
Aciclovir Apotex 200 mg tabletten RVG 118926 2017-09-29 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Aciclovir Apotex 200 mg tabletten 2. QUALITATIVE AND QUANTITATIVE COMPOSITION
More informationZOVIRAX ORAL FORMULATIONS GlaxoSmithKline
ZOVIRAX ORAL FORMULATIONS GlaxoSmithKline Aciclovir QUALITATIVE AND QUANTITATIVE COMPOSITION Tablets containing either 200 mg, 400 mg or 800 mg aciclovir; Dispersible tablets containing either 200 mg,
More informationNHS Greater Glasgow & Clyde SOP No. BMT Haemopoietic Stem Cell Transplantation Services Vaccination Policy
This policy was written with advice from Dr S Ahmed, Consultant in Public Health, Greater Glasgow & Clyde. We would like to thank him for his guidance. 1. Background It is recommended by EBMT and CDC that
More informationNo Assessment Director of Nursing and Operations, DIPC
Shropshire Community Health NHS Trust Document Details Title Management of Chickenpox and Shingles Policy Trust Ref No 759-28158 Local Ref (optional) Main points the document This policy details guidance
More informationACIVIR I.V. Injection (Aciclovir)
Published on: 22 Sep 2014 ACIVIR I.V. Injection (Aciclovir) Composition ACIVIR I.V. Each ml contains: Aciclovir BP... 25 mg Water for Injection IP...q.s. Dosage Form Injection for I.V. use Pharmacology
More informationDepartment of Health. Year 8. vaccination program. Important information for parents and students
Department of Health Year 8 vaccination program Important information for parents and students Contents Why immunise? 1 Vaccination program 1 Schedule of vaccinations 2 Vaccination records 2 Vaccine safety
More informationIMOGAM RABIES PASTEURIZED - HUMAN RABIES IMMUNOGLOBULIN. Active ingredient: Human proteins mg
IMOGAM RABIES PASTEURIZED - HUMAN RABIES IMMUNOGLOBULIN COMPOSITION 1 ml of human rabies immunoglobulin contains: Active ingredient: Human proteins 100 180 mg containing (IgG class) human rabies immunoglobulins
More informationHealthcare Personnel Immunization. Ruth Carrico PhD RN FSHEA CIC Associate Professor Division of Infectious Diseases University of Louisville
Healthcare Personnel Immunization Ruth Carrico PhD RN FSHEA CIC Associate Professor Division of Infectious Diseases University of Louisville Disclosures Funding provided by the U. S. Department of Homeland
More informationAged 70 or 78? There s now a vaccine to help protect you against shingles
Aged 70 or 78? There s now a vaccine to help protect you against shingles This leaflet describes shingles and the benefits of the vaccination. The new shingles vaccine is being phased in over the next
More informationDarren J. Guffey, MD; Sarah B. Koch, MD, MBA; Leonora Bomar, MD; William W. Huang, MD, MPH
PEDIATRIC DERMATOLOGY Herpes Zoster Following Varicella Vaccination in Children Darren J. Guffey, MD; Sarah B. Koch, MD, MBA; Leonora Bomar, MD; William W. Huang, MD, MPH PRACTICE POINTS Most children
More informationImmunization for Child Hematopoietic Stem Cell Transplant (HSCT) Recipients
Immunization for Child Recipients January 4, 201 Immunization for Child Hematopoietic Stem Cell Transplant () Recipients Revision Date: January 4, 201 Note: This guide is meant to supplement existing recommendations
More informationZoster Vaccine for Older Adults
BC Centre for Disease Control IMMUNIZATION FORUM 29 Zoster Vaccine for Older Adults Michael N. Oxman, M.D. Professor of Medicine and Pathology University of California, San Diego VASDHS Staff Physician
More informationProducts available Methotrexate tablets 2.5mg ONLY (Methotrexate tablets 10mg are NOT recommended as per NPSA guidance 5 ).
Methotrexate Traffic light classification- Amber 1 Information sheet for Primary Care Prescribers Part of the Shared Care Protocol: Management of Rheumatological Conditions with Disease-Modifying Anti
More informationMeasles. Chapter 12 Measles. Measles. Measles vaccine introduced in 1985/ MMR introduced in 1988 NOTIFIABLE
Chapter 12 12 vaccine introduced in 1985/ MMR introduced in 1988 NOTIFIABLE In some circumstances, advice in these guidelines may differ from that in the Summary of Product Characteristics of the vaccines.
More informationLECTURE OUTLINE. B. AGENT: Varicella-zoster virus. Human herpes virus 3. DNA virus.
Viral Vaccines II LECTURE OUTLINE 5/24/04 I. CASE HISTORY A 5-year old comes home from school with a red skin rash on his chest that spreads to over 300 itchy blisters that spread further to his face,
More informationClinical Aspect and Application of Laboratory Test in Herpes Virus Infection. Masoud Mardani M.D,FIDSA
Clinical Aspect and Application of Laboratory Test in Herpes Virus Infection Masoud Mardani M.D,FIDSA Shahidhid Bh BeheshtiMdi Medical lui Universityit Cytomegalovirus (CMV), Epstein Barr Virus(EBV), Herpes
More informationViruses. Poxviridae. DNA viruses: 6 families. Herpesviridae Adenoviridae. Hepadnaviridae Papovaviridae Parvoviridae
Viruses DNA viruses: 6 families Poxviridae Herpesviridae Adenoviridae Hepadnaviridae Papovaviridae Parvoviridae Human herpesviruses Three subfamilies (genome structure, tissue tropism, cytopathologic effect,
More informationIf your IBD has not been well controlled, or is flaring up quite often, tacrolimus may be added to your treatment.
If your IBD has not been well controlled, or is flaring up quite often, tacrolimus may be added to your treatment. What is tacrolimus? Patient Information Drugs for Inflammatory Bowel Disease Tacrolimus
More informationTopic BKV Polyoma Virus
Topic 13.1. BKV Polyoma Virus Author: Helen Pilmore and Paul Manley GUIDELINES a. We suggest screening high risk kidney transplant recipients for BK polyoma virus (BKV) with quantitative plasma NAT. The
More informationI hope the shared cared protocol will help with your care of this renal transplant patient. We are happy to discuss any issues with you.
Paediatric Nephrology Phone (64) 9-3078900 Fax (64) 9-3078938 renalnurse@adhb.govt.nz wwong@adhb.govt.nz tonyak@adhb.govt.nz stackm@adhb.govt.nz chanelp@adhb.govt.nz Dear Colleague, Thank you for resuming
More informationI hope the shared cared protocol will help with your care of this renal transplant patient. We are happy to discuss any issues with you.
Paediatric Nephrology Phone (64) 9-3078900 Fax (64) 9-3078938 renalnurse@adhb.govt.nz wwong@adhb.govt.nz tonyak@adhb.govt.nz stackm@adhb.govt.nz chanelp@adhb.govt.nz Dear Colleague, Thank you for resuming
More informationChild cancer scenarios. GP CME Rotorua 2014
Child cancer scenarios GP CME Rotorua 2014 Scenario 1 Chickenpox is in the school What is the response when the parent of a child on chemotherapy rings the practice? Scenario 2 -chickenpox Varicella is
More informationImmunization Update Richard M. Lampe M.D.
Immunization Update 2012 Richard M. Lampe M.D. Immunization Update List the Vaccines recommended for Health Care Personnel Explain why Health Care Personnel are at risk Recognize the importance of these
More informationSV/SPC/ SUMMARY OF PRODUCT CHARACTERISTICS
SV/SPC/20160315 1 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT GammaQuin 160 g/l solution for injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Human normal immunoglobulin (SC/IMIg)
More informationAllied Health STUDENT HEALTH AND SAFETY DOCUMENTATION CHECKLIST
A. MMR (Measles/Rubeola, Mumps, & Rubella) MMR is a combined vaccine that protects against three separate illnesses measles, mumps and rubella (German measles) in a single injection. Measles, mumps, and
More informationThe Management of Chickenpox/Shingles, including screening Processes Policy
The Management of Chickenpox/Shingles, including screening Processes Policy This policy describes the processes and procedures for management of Chickenpox and Shingles. Key Words: Shingles, chickenpox
More informationEffective Shared Care Agreement (ESCA)
Effective Shared Care Agreement (ESCA) Azathioprine (either alone or more usually in combination with corticosteroids and/or other drugs and procedures) ESCA: For the treatment of systemic lupus erythematosus
More informationTrust Guideline for the Use of Parenteral Vancomycin and Teicoplanin in Adults
A clinical guideline recommended for use: In: By: For: Division responsible for document: Key words: Names of document authors: Job titles of document authors: Name of document author s Line Manager: Job
More informationVaricella and varicella vaccination An update
THEME: School contagions Varicella and varicella vaccination An update John Litt, Margaret Burgess BACKGROUND Although varicella is generally mild in children, it is often more severe in adults and overall
More informationIMMUNIZATION PROTOCOLS FOR PHARMACISTS. VARICELLA Live Virus Vaccine
IMMUNIZATION PROTOCOLS FOR PHARMACISTS VARICELLA Live Virus Vaccine I. ORDER: 1. Screen for contraindications and evidence of immunity (Section VII.K.) 2. Provide a current Vaccine Information Statement
More informationHuman Herpes Viruses (HHV) Mazin Barry, MD, FRCPC, FACP, DTM&H Assistant Professor and Consultant Infectious Diseases KSU
Human Herpes Viruses (HHV) Mazin Barry, MD, FRCPC, FACP, DTM&H Assistant Professor and Consultant Infectious Diseases KSU HERPES VIRUS INFECTIONS objectives: ØTo know the clinically important HHVs. ØTo
More informationNegri Body and EM of Rabies Virus
Rhabdovirus Nearly 100% fatal after symptoms appear Bullet shaped virion Helical nucleocapsid Zoonotic Glycoprotein Binds to Nicotinic Ach receptors in the post-synaptic junction. Replicates in motor neurons
More information